XBiotech Inc.
XBIT
$8.44
-$0.17-1.97%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -96.35% | -82.08% | -75.01% | -78.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -96.35% | -82.08% | -75.01% | -78.20% |
| Cost of Revenue | -- | -99.05% | -91.03% | -88.25% | -88.81% |
| Gross Profit | -- | -95.65% | -79.36% | -70.22% | -73.29% |
| SG&A Expenses | -26.05% | -28.88% | -37.04% | -36.05% | -32.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.57% | -10.42% | -11.88% | -14.09% | -11.45% |
| Operating Income | -8.76% | -10.63% | -13.25% | -15.03% | -37.50% |
| Income Before Tax | 27.61% | 42.52% | 24.00% | -7.34% | -31.93% |
| Income Tax Expenses | 135.32% | 137.29% | 145.23% | 103.87% | 91.45% |
| Earnings from Continuing Operations | 25.36% | 36.06% | -6.17% | -54.74% | -88.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.36% | 36.06% | -6.17% | -54.74% | -88.93% |
| EBIT | -8.76% | -10.63% | -13.25% | -15.03% | -37.50% |
| EBITDA | -12.20% | -15.28% | -17.34% | -18.04% | -42.08% |
| EPS Basic | 25.34% | 36.06% | -6.10% | -54.00% | -86.91% |
| Normalized Basic EPS | 27.61% | 42.53% | 24.05% | -6.71% | -30.51% |
| EPS Diluted | 25.05% | 36.08% | -6.07% | -53.93% | -86.81% |
| Normalized Diluted EPS | 27.61% | 42.53% | 24.05% | -6.71% | -30.51% |
| Average Basic Shares Outstanding | 0.00% | 0.02% | 0.10% | 0.48% | 1.33% |
| Average Diluted Shares Outstanding | 0.00% | 0.02% | 0.10% | 0.48% | 1.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
